These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 20151319)

  • 21. Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane.
    Bahrami N; Chang G; Kanaya N; Sauer T; Park D; Loeng M; Gravdehaug B; Chen S; Geisler J
    J Steroid Biochem Mol Biol; 2020 Jun; 200():105641. PubMed ID: 32151708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary hormone treatment in postmenopausal women with breast cancer.
    Maciá Escalante S; Pons Sanz V; Rodríguez Lescure A; Ballester Navarro I; Carrato Mena A
    Clin Transl Oncol; 2006 May; 8(5):372-4. PubMed ID: 16760014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma.
    Utsunomiya H; Ito K; Suzuki T; Kitamura T; Kaneko C; Nakata T; Niikura H; Okamura K; Yaegashi N; Sasano H
    Clin Cancer Res; 2004 Sep; 10(17):5850-6. PubMed ID: 15355916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma.
    Suzuki T; Nakata T; Miki Y; Kaneko C; Moriya T; Ishida T; Akinaga S; Hirakawa H; Kimura M; Sasano H
    Cancer Res; 2003 Jun; 63(11):2762-70. PubMed ID: 12782580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.
    Kurozumi S; Yamaguchi Y; Matsumoto H; Kurosumi M; Hayashi SI; Fujii T; Horiguchi J; Shirabe K; Inoue K
    PLoS One; 2019; 14(5):e0217279. PubMed ID: 31112577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aromatase inhibitors and breast cancer prevention.
    Litton JK; Arun BK; Brown PH; Hortobagyi GN
    Expert Opin Pharmacother; 2012 Feb; 13(3):325-31. PubMed ID: 22242911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers.
    Purohit A; Foster PA
    J Endocrinol; 2012 Feb; 212(2):99-110. PubMed ID: 21859802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
    Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].
    Semiglazov VF; Semiglazov VV; Dashian GA; Zhil'tsova EK; Ivanov VG; Bozhok AA; Tonuzov EE; Paltuev RM; Mel'nikova OA; Klettsel' AA; Krivorot'ko PV; Donskikh RV; Kochetova IA; Damenia AO; Zernov KIu; Voskresenskiĭ DA; Bershteĭn LM
    Vopr Onkol; 2007; 53(4):400-8. PubMed ID: 17969401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas.
    Takagi M; Miki Y; Miyashita M; Hata S; Yoda T; Hirakawa H; Sagara Y; Rai Y; Ohi Y; Tamaki K; Ishida T; Suzuki T; Ouchi N; Sasano H
    Breast Cancer Res Treat; 2016 Feb; 156(1):45-55. PubMed ID: 26943913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
    Nakata T; Takashima S; Shiotsu Y; Murakata C; Ishida H; Akinaga S; Li PK; Sasano H; Suzuki T; Saeki T
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):455-60. PubMed ID: 14623544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.
    Yamashita H; Takahashi S; Ito Y; Yamashita T; Ando Y; Toyama T; Sugiura H; Yoshimoto N; Kobayashi S; Fujii Y; Iwase H
    Cancer Sci; 2009 Nov; 100(11):2028-33. PubMed ID: 19659610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
    Day JM; Foster PA; Tutill HJ; Parsons MF; Newman SP; Chander SK; Allan GM; Lawrence HR; Vicker N; Potter BV; Reed MJ; Purohit A
    Int J Cancer; 2008 May; 122(9):1931-40. PubMed ID: 18183589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
    Kuter I; Gee JM; Hegg R; Singer CF; Badwe RA; Lowe ES; Emeribe UA; Anderson E; Sapunar F; Finlay P; Nicholson RI; Bines J; Harbeck N
    Breast Cancer Res Treat; 2012 May; 133(1):237-46. PubMed ID: 22286314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.
    Tubiana-Hulin M; Becette V; Bieche I; Mauriac L; Romieu G; Bibeau F; Macgrogan G; Bourgeois H; Chollet P; Defrance R; Spyratos F
    Anticancer Res; 2007; 27(4C):2689-96. PubMed ID: 17695434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
    Polychronis A; Sinnett HD; Hadjiminas D; Singhal H; Mansi JL; Shivapatham D; Shousha S; Jiang J; Peston D; Barrett N; Vigushin D; Morrison K; Beresford E; Ali S; Slade MJ; Coombes RC
    Lancet Oncol; 2005 Jun; 6(6):383-91. PubMed ID: 15925816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
    Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
    Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.